Theracurmin® Super, The Most Advanced Form of Curcumin in Bioavailability, Will Make a Debut in Europe at the Vitafoods Exhibition
TOKYO, April 25, 2017 /PRNewswire/ -- Theravalues Corporation (Tokyo, Japan) is proud to announce the launch of Theracurmin® Super for the European market at Vitafoods Europe 2017 (Geneva, May 9-11).
It is a new and advanced form of curcumin with dramatically higher bioavailability which is 2.7 times more than the existing Theracurmin®. Theracurmin® Super has been developed based on two different technologies: (1) a unique amorphous (non-crystal) producing technology and (2) a stabilizing technology.
All ingredients used in the Theracurmin® Super are approved by European regulations.
Curcumin is a yellow pigment contained in the spice turmeric (Curcuma longa) that has been known as antioxidant, anti-inflammatory, anticancer, antiviral, and antibacterial activities.
Despite its range of reported pharmacological effects, including anti-oxidant, anti-inflammatory, and anti-tumor, curcumin is limited in its clinical applicability due to its low bioavailability.
The current curcumin product from Theravalues, Theracurmin® proved 27 times higher bioavailability than ordinary curcumin powder. It has been studied in many human clinical trials over the world and obtained many significant positive results. There are 24 papers published and 22 clinical trials completed including 16 RCTs (randomized controlled trial).
Major clinical studies published
Brain Health |
Improvement of memory and attention functions |
Joint Health |
Significant decrease of pain score and dependency on the NSAIDs (Non-steroid anti-inflammation drug) |
Cardiovascular health |
Improvement of carotid artery stiffness and other functions |
Heart health |
Improvement of diastolic dysfunction |
Liver Health |
Improvement of liver function makers of gamma-GTP, AST and ALT |
Sports Nutrition |
Acceleration of muscle fatigue recovery and attenuation of oxidative stress induced by exercise |
Theracurmin® Super has proven 2.7 times higher bioavailability than Theracurmin® under the double-blind cross-over human clinical trial. With its extraordinary high bioavailability, Theracurmin® Super will make a huge contribution to treatment and prevention of a number of diseases in many countries, where aging populations rapidly grow.
Theravalues Corporation will exhibit at Vitafoods Europe, Geneva (Stand J166), and be pleased to share the details of the product information with visitors.
A seminar on Theracurmin® Super will also be provided on May 9th at Vitafoods Europe as follows;
Session Title: Theracurmin® The Most Advanced Form of Curcumin in Bioavailability
May 9, 2017 16:20-16:50 @ Exhibitor Presentation Theatre
About Theravalues Corporation
Theravalues Corporation (1F Kioicho Bldg., 3-12 Kioicho, Chiyoda-ku, Tokyo 102-0094 Japan) is a leading biotechnology innovator in the health and supplement industry. Based in Tokyo, Japan, it actively researches and develops natural and bio-engineered ingredients that have proven health benefits. Its major product, Theracrumin® - one of the most advanced forms of curcumin in the marketplace, is used in a variety of dietary supplements in North America, Oceania and Asia.
For more information, visit: www.theravalues.com/english/
Photo - http://mma.prnewswire.com/media/492735/Theravalues_Theracurmin_Super.jpg
Share this article